ERBB2 and breast carcinoma: This was clearly demonstrated for breast cancer, in which low Claspin expression was correlated with a worse overall survival but only when tumor cells concomitantly presented p53 inactivation (apoptosis resistance) or HER2 over-expression (increased proliferation and survival signals; resistance to apoptosis induction), the opposite being observed in cells with wt TP53 (which can still be induced to die by apoptosis) or low-to-negative expression of HER2 (lower survival signals; higher sensitivity to apoptosis induction) [80].